Latest news
Antibody Drug Shows Promise in Refractory Lymphoma - MedscapeMedscape · Fri, 07 Aug 2026 12:00:41 GMTLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - globenewswire.comglobenewswire.com · Thu, 06 Aug 2026 20:05:00 GMTBridging to CAR T-cell therapy in LBCL with CD20 × CD3 BsAbs vs conventional treatment - Lymphoma HubLymphoma Hub · Mon, 03 Aug 2026 10:29:10 GMTFDA grants RMAT and fast track designation to cema-cel for first-line consolidation in MRD-positive LBCL - Lymphoma HubLymphoma Hub · Thu, 30 Jul 2026 19:46:39 GMTFDA Grants Fast Track and RMAT Designations to Cema-Cel in LBCL - Targeted OncologyTargeted Oncology · Thu, 30 Jul 2026 19:15:53 GMTCema-Cel Receives FDA RMAT, Fast Track Designations in First-Line LBCL - CancerNetworkCancerNetwork · Thu, 30 Jul 2026 15:07:19 GMTAllogene's Cema-Cel Receives FDA RMAT and Fast Track Designations for First-Line LBCL Consolidation - BioPharm InternationalBioPharm International · Wed, 29 Jul 2026 17:22:39 GMTFDA Grants RMAT and Fast Track Designations to Cema-Cel for First-Line LBCL - onclive.comonclive.com · Wed, 29 Jul 2026 07:00:00 GMT